In a phase III trial of 366 participants aged 3-8 years (of 1412 planned, lowering power), RIV4 gave non-inferior immune responses to IIV4 for A/H1N1, A/H3N2 and B/Yamagata strains but not B/Victoria; both were well tolerated.
RCTn = 366
Folegatti et al. Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8 years: results from a phase III randomised study